ASN's Mission

To create a world without kidney diseases, the ASN Alliance for Kidney Health elevates care by educating and informing, driving breakthroughs and innovation, and advocating for policies that create transformative changes in kidney medicine throughout the world.

learn more

Contact ASN

1401 H St, NW, Ste 900, Washington, DC 20005

email@asn-online.org

202-640-4660

The Latest on X

Kidney Week

Abstract: FR-PO1062

A Multicentre, Stepped-Wedge Cluster Randomised Trial of a Complex Intervention to Reduce Harm Associated with AKI

Session Information

Category: Acute Kidney Injury

  • 003 AKI: Clinical and Translational

Authors

  • Selby, Nicholas M., University of Nottingham, Nottingham, United Kingdom
  • Casula, Anna, UK Renal Registry, Bristol, United Kingdom
  • Lamming, Laura, University of Bradford, Bradford, United Kingdom
  • Stoves, John, Bradford Teaching Hospitals NHS Foundation Trust, Bradford, United Kingdom
  • Samarasinghe, Yohan P, Frimley Park Hospital, Camberley, United Kingdom
  • Lewington, Andrew J.P., Leeds Teaching Hospitals, Leeds, United Kingdom
  • Roberts, Russell, Bradford Teaching Hospitals NHS Foundation Trust, Bradford, United Kingdom
  • Shah, Nikunj, Ashford & St Peters Hospitals NHS Foundation Trust, Chertsey, United Kingdom
  • Fluck, Richard J., Royal Derby Hospital, Derby, United Kingdom
  • Johnson, Mel J, Yorkshire & Humber Improvement Academy, Bradford, United Kingdom
  • Jackson, Natalie, Yorkshire & Humber Improvement Academy, Bradford, United Kingdom
  • Jones, Carol A, Ashford & St Peters Hospitals NHS Foundation Trust, Chertsey, United Kingdom
  • Caskey, Fergus J., UK Renal Registry, Bristol, United Kingdom

Group or Team Name

  • Tackling AKI investigators
Background

Acute kidney injury (AKI) is common and associated with poor outcomes. We sought to evaluate the effectiveness, at the hospital level, of a package of measures to reduce harm associated with AKI.

Methods

A multi-centre, pragmatic, stepped-wedge cluster randomised trial (SWCRT) was performed in five UK hospitals. The organisation-wide intervention consisted of AKI alerts, a care bundle and an educational program that was introduced sequentially across fixed three month periods until all hospitals were ultimately exposed to the intervention. The sequence was determined by random number generation. All patients with AKI aged ≥18 years hospitalised for >1day were included. Chronic dialysis was the only exclusion criterion. Data were collected in 3 month periods, with a minimum of 2 pre-exposure (control), one transition and a minimum of one exposed periods per site. The primary outcome was 30-day mortality associated with AKI, with pre-specified secondary endpoints and a nested evaluation of care process delivery.

Results

24,059 AKI episodes were studied (incidence 7.6 cases/100 admissions); mean age was 72±17yrs; 62% had AKI stage 1, 21% AKI stage 2, 17% AKI stage 3. Overall 30d mortality was 24.5%, with no difference between control and intervention periods (OR 1.07, 95% CI 0.93-1.24). Hospital length of stay (LoS) was reduced in the intervention period; -0.2days (95% CI -0.4 to 0.1), -0.7days (-1.3 to -0.1) and -1.3days (-2.7 to 0.1) for tertiles with low, middle and high LoS, respectively. The incidence of AKI increased in the intervention period, likely reflecting improved AKI detection.
Process measures were assessed in 1042 patients. In the intervention period, improvements were seen in several metrics including AKI recognition, medication optimization, fluid assessment and urinalysis; care bundle usage was 40% with variation between centres (range 15-68%). The degree of improvement differed between centres, which will be explored in a qualitative analysis.

Conclusion

A complex, hospital-wide intervention to reduce harm associated with AKI resulted in improvements in delivery of care, improved AKI detection and a modest reduction in LoS, but did not alter AKI mortality.

Funding

  • Private Foundation Support